Month: January 2022

Stock Market Analysis

Abiomed’s Less Troubled 2020 Justifies Multiple, But Medium-Term Headwinds Mean Capital Risk

by Valkyrie Trading Society
Contributor since 2019 / 3361 Followers

3 years ago

Summary: Abiomed is a company with a superb product in the mid-market space while what

Stock Market Analysis

360 DigiTech: Cheap Shares And Now A 5.6% Dividend Yield To Boot

by Shareholders Unite
Contributor since 2008 / 18528 Followers

3 years ago

Summary: The company keeps on growing and shifting its business model to platform services where

Stock Market Analysis

Merck And Absci: AI-Driven Drug Development Deal Has Promise, But May Take Years To Pay Out

by Edmund Ingham
Contributor since 2018 / 8482 Followers

3 years ago

Summary: Absci, a Vancouver-based drug discovery company that IPOd in July last year, has seen